MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results 16.11.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 16, 2022 MorphoSys AG...

Related Keywords

Germany ,Louisiana ,United States ,New Orleans ,United Kingdom ,Planegg ,Bayern ,Massachusetts ,Boston ,Canada ,American ,Monjuvi Minjuvi ,Thomas Biegi ,Tim Demuth ,Julia Neugebauer ,Eamonn Nolan ,Jean Paul Kress ,Md Tim Demuth ,Janssen Biotech Inc ,American Society Of Hematology Annual Meeting ,Xencor Inc ,Linkedin ,Twitter ,Drug Administration ,Nasdaq ,Distribution Services ,Exchange Commission ,Morphosys Group Key Figures ,Development Rd Expenses ,Share Of Loss Associates ,Society Of Hematologic Oncology ,Interim Statement ,First Nine Months ,Third Quarter ,Chief Executive Officer ,Data Highlights ,Hematologic Oncology ,Molecular Targets ,American Society ,Hematology Annual Meeting ,Chief Research ,Development Officer ,Malte Peters ,Events After ,Net Loss ,Royalty Pharma ,Full Year ,Sys Group Key Figures ,Impairment Losses ,Tax Benefit ,Net Profit ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Janssen Biotech ,Morphosy Annual Report ,Corporate News ,Regulatory Announcements ,